Febrile Neutropenia

The Multinational Association for Supportive Care in Cancer (MASCC) risk index can be used to identify low-risk patients (score cut off at 21 points) for serious complications of febrile neutropenia. Per 2010 guidelines from Infectious Diseases Society of America

• Cefepime, carbapenems or piperacillin/tazobactam are recommended for high-risk patients and 
• Co-amoxiclav and ciprofloxacin are recommended for low-risk patients. 

Patients who do not strictly fulfill the criteria of low-risk patients should be admitted to the hospital and treated as high-risk patients.